SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Earnings webcast details:
• Location: | http://investor.resmed.com |
• Date: | Thursday, April 25, 2024 |
• Time: | 1:30 p.m. PDT / 4:30 p.m. EDT |
• International: | London, Thursday, April 25, 2024, 9:30 p.m. BST Sydney, Friday, April 26, 2024, 6:30 a.m. AEST |
Please note, ResMed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.
A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from April 25, 2024, until May 9, 2024, at:
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
For investors +1 858.836.5000 This email address is being protected from spambots. You need JavaScript enabled to view it. | For media +1 619.510.1281 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$247.05 |
Daily Change: | 3.02 1.24 |
Daily Volume: | 539,912 |
Market Cap: | US$36.270B |
May 01, 2025 April 03, 2025 January 30, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load